23andMe Holding Future Growth

Future criteria checks 1/6

23andMe Holding is forecast to grow revenue at 11.9% per annum. EPS is expected to grow by 48.1% per annum.

Key information

n/a

Earnings growth rate

48.1%

EPS growth rate

Healthcare earnings growth19.3%
Revenue growth rate11.9%
Future return on equity-81.7%
Analyst coverage

Low

Last updated10 Aug 2024

Recent future growth updates

Recent updates

Here's Why We're A Bit Worried About 23andMe Holding's (NASDAQ:ME) Cash Burn Situation

Apr 16
Here's Why We're A Bit Worried About 23andMe Holding's (NASDAQ:ME) Cash Burn Situation

Risks Still Elevated At These Prices As 23andMe Holding Co. (NASDAQ:ME) Shares Dive 26%

Mar 02
Risks Still Elevated At These Prices As 23andMe Holding Co. (NASDAQ:ME) Shares Dive 26%

We're Keeping An Eye On 23andMe Holding's (NASDAQ:ME) Cash Burn Rate

Jul 13
We're Keeping An Eye On 23andMe Holding's (NASDAQ:ME) Cash Burn Rate

23andMe Holding Co. (NASDAQ:ME) Investors Are Less Pessimistic Than Expected

Jun 15
23andMe Holding Co. (NASDAQ:ME) Investors Are Less Pessimistic Than Expected

23andMe: Disappointing Results Could Mean Potential Acquisition Target

Sep 27

23andMe: Treacherous Path To Profitability

Aug 26

23andMe drops 8% as CFO resigns

Aug 19

23andMe Holding Co. (NASDAQ:ME) Just Reported, And Analysts Assigned A US$5.00 Price Target

Aug 11
23andMe Holding Co. (NASDAQ:ME) Just Reported, And Analysts Assigned A US$5.00 Price Target

23andMe Q1 2023 Earnings Preview

Aug 07

23andMe: Holiday Miracles Not Enough, Growth Path Too Expensive

Jun 15

23andMe: A Genetics Innovator Positioned For Growth

Feb 19

Need To Know: Analysts Are Much More Bullish On 23andMe Holding Co. (NASDAQ:ME) Revenues

Feb 18
Need To Know: Analysts Are Much More Bullish On 23andMe Holding Co. (NASDAQ:ME) Revenues

23andMe: No Surprises With Recent Earnings, But Long-Term Story Remains Positive

Nov 21

23andMe Stock: Continued Drug-Development Progress Can Deliver Long-Term Gains

Oct 03

Companies Like 23andMe Holding (NASDAQ:ME) Are In A Position To Invest In Growth

Sep 17
Companies Like 23andMe Holding (NASDAQ:ME) Are In A Position To Invest In Growth

23andMe: New Therapeutic Pipeline And PGS Product Growth Catalyzed By +$696M In SPAC Funding

Jul 19

Earnings and Revenue Growth Forecasts

NasdaqCM:ME - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/2027251N/AN/AN/A1
3/31/2026252N/AN/AN/A2
3/31/2025167N/AN/AN/A1
6/30/2024199-631-146-138N/A
3/31/2024220-667-174-164N/A
12/31/2023248-522-194-183N/A
9/30/2023270-336-158-146N/A
6/30/2023296-327-173-162N/A
3/31/2023299-312-177-165N/A
12/31/2022308-317-167-156N/A
9/30/2022298-315-216-206N/A
6/30/2022277-265-211-195N/A
3/31/2022272-217-181-167N/A
12/31/2021260-215-183-172N/A
9/30/2021259-170-130-119N/A
6/30/2021255-190-90-86N/A
3/31/2021244-184-82-74N/A
3/31/2020305-251-259-186N/A
3/31/2019441-184-126-98N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if ME's forecast earnings growth is above the savings rate (2.5%).

Earnings vs Market: Insufficient data to determine if ME's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if ME's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: ME's revenue (11.9% per year) is forecast to grow faster than the US market (8.7% per year).

High Growth Revenue: ME's revenue (11.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ME is forecast to be unprofitable in 3 years.


Discover growth companies